Nebicard (Nebivolol Hydrochloride)

Nebivolol hydrochloride, the active ingredient in Nebicard, is a beta‑blocker presented as an oral tablet for oral use. It is employed to lower high blood pressure and to improve outcomes in patients with chronic heart failure, acting selectively on β1‑adrenergic receptors while enhancing nitric‑oxide mediated vasodilation.

GNH USA supplies Nebicard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand through reliable logistics.

Nebicard, a selective β1‑adrenergic antagonist, is used in cardiovascular conditions that involve elevated blood pressure or impaired cardiac function.

Essential hypertension: reduces systolic and diastolic blood pressure to target levels. Chronic heart failure: improves left ventricular ejection fraction and reduces hospitalization risk. Hypertension with left ventricular dysfunction: provides blood pressure control while supporting cardiac performance.

Nebicard may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness or reduced energy. - Headache: mild to moderate cranial pain. - Dizziness: sensation of light‑headedness, especially on standing. - Bradycardia: slower than normal heart rate. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Symptomatic hypotension: significant drop in blood pressure causing faintness. - Bronchospasm: tightening of airway muscles, particularly in patients with asthma. - Heart block: impaired electrical conduction in the heart. - Allergic reactions: rash, swelling, or anaphylaxis.

When prescribing Nebicard, clinicians should consider several safety measures to minimise risk. - Blood pressure monitoring: check baseline and periodic readings. - Cardiac function assessment: evaluate heart rate and ECG before initiation. - Concomitant beta‑blocker use: avoid combining with other β‑blockers or non‑selective agents. - Respiratory disease caution: use carefully in patients with asthma or COPD. - Renal/hepatic impairment: dose may need adjustment in reduced clearance. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Nebicard can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other beta‑blockers: additive cardiac depression. - Calcium channel blockers verapamil or diltiazem: increased risk of AV‑block and bradycardia. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): raise nebivolol plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effect. - ACE inhibitors or ARBs: combined use can enhance blood pressure lowering.